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Abstract: A 4-year-old intact female dog was presented with a vaginal transmissible venereal tumor (TVT) that had clinically developed
multidrug resistance to vincristine, vinblastine, and doxorubicin. Complete remission was obtained with combined-modality therapy
with surgery, L-asparaginase, and prednisone.
Key words: Cancer, Sticker tumor, transmissible venereal tumor

1. Introduction
A transmissible venereal tumor (TVT) is a horizontally
transmitted venereal round cell tumor diagnosed in dogs
(1,2). It is normally transmitted during coitus by viable
tumor cells through injured mucosa. TVTs are usually
located on genital, oral, or nasal mucosa (2). Initially
the tumor is small, subsequently progressing to a large,
ulcerated, and contaminated mass. The lesions are friable,
hyperemic, hemorrhagic, multilobular, cauliflowerlike masses (3). TVTs are locally aggressive and rarely
metastatic. Definitive diagnosis is based on cytological and
histological findings. Differential diagnosis includes round
cell tumors such as lymphoma, plasma cell tumor, and
mast cell tumor (4). The most effective treatment for TVT
is chemotherapy with vincristine sulfate administered
weekly (0.5 to 1 mg/m2, IV) for 4 to 6 weeks (5,6). Resistant
cases can be treated with doxorubicin (30 mg/m2, IV)
every 21 days (2 or 3 cycles) (4). When TVT becomes
chemotherapy-resistant, treatment becomes a challenge
(2,4,7). This report describes a bitch with TVT that had
clinically developed resistance to vincristine, vinblastine,
and doxorubicin and was successfully treated with surgery
resection, L-asparaginase, and prednisone.
2. Case history
A 4-year-old, intact female, mixed-breed dog was referred
to the Oncology Service of the Veterinary Teaching
Hospital of the Federal University of Parana (HV-UFPR),
Curitiba, Brazil, with a history of vaginal TVT previously
treated with chemotherapy with partial regression. The
* Correspondence: danimsca@hotmail.com
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dog had been adopted from the street 6 months before
the beginning of treatment. Vincristine sulfate was
administered for 8 weeks and partial regression of the
tumor was observed. Subsequently, the dog was treated
with 2 doses of vinblastine weekly without clinical
response. Next, 4 cycles of doxorubicin were administered
without tumor regression.
Upon admission at HV-UFPR, multiple hyperemic
vaginal nodules were observed. Masses were friable and
the tumor size was 5 mm in diameter (Figure 1A). TVT
was diagnosed by imprint cytology (Figure 1B). The
results of complete blood cell count (CBC) and blood
chemistry tests were within reference intervals. Following
diagnosis of TVT, surgical excision of tumors and
ovariohysterectomy (OH) were performed under general
anesthesia. OH was performed before tumor excision
via abdominal laparotomy. En bloc excision included the
vaginal vestibule, vulvar labia, and tumors and was done
after episiotomy.
Histopathology from the vagina and vulva showed
confluent sheets of neoplastic round cells growing in cords
that were infiltrating into the submucosa and muscle,
confirming TVT (Figure 1C). Neoplastic cells were present
around the surgical margins. Infiltration of lymphocytes
and plasma cells was also observed. Histopathology
of the uterus and ovaries was unremarkable. Six days
after surgery, chemotherapy was initiated with 1 dose of
L-asparaginase (400 UI/kg, SC) and oral prednisone (2
mg/kg, once a day for a week). The prednisone dose was
then reduced weekly to 1.5 mg/kg, 1 mg/kg, and 0.5 mg/
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kg. Thirteen days after surgery, the dog was alert and the
surgery site had healed (Figure 1D). A CBC disclosed mild
neutrophilia [15.3 × 103/µL, reference range (RR): 3 to 11.5
× 103/µL] and lymphopenia (322/µL, RR: 1000 to 4800/
µL). Blood chemistry tests were within reference intervals.
Imprint cytology of the vulvar area was performed 1
month after surgery and did not show neoplastic cells.
Six months after surgery, the patient returned for
an oncological evaluation and a vaginal nodule of 3
mm in diameter was observed (Figure 2A). Cytological
examination of the lesion was unremarkable. An
excisional biopsy reveled lymphocytes and plasma cell
infiltration, indicating a subacute inflammatory process,
without neoplastic cells (Figure 2B). Therefore, no further

A

treatment was introduced. One year after treatment
the tumor had not recurred and there was a remarkable
improvement in the patient’s quality of life.
3. Discussion
In general, vincristine sulfate as a single agent administered
weekly for up to 6 cycles yields a cure for TVT. However,
resistance to vincristine has been frequently observed
in TVT patients. Resistance to chemotherapy should
be considered when a residual tumor is present after
6 treatment cycles (7,8). In the present case, previous
treatment details such as chemotherapy doses, application
interval, clinical remission, and tumor reappearance were
unknown. These factors might have predisposed TVT
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Figure 1. A) Multiple hyperemic vaginal nodules. B) Cytology of canine transmissible venereal tumor from a vaginal
mass aspiration. Moderate amount of cells with coarse chromatin and smoky vacuolated cytoplasm. Wright’s stain,
40×. C) Histology of canine transmissible venereal tumor. Round to ovoid neoplastic cells (arrow) arranged in short
cords. H&E stain, 10×. D) Surgical site 13 days after surgery.
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Figure 2. A) Nodule on vaginal mucosa 6 months after TVT
treatment. B) Histopathology from nodule located on vaginal
mucosa showing presence of mild lymphoplasmacytic infiltration
(arrow) just below the epithelial lining; neoplastic cells were not
observed. H&E stain, 40×.

chemotherapy resistance to vincristine and doxorubicin.
There are several mechanisms by which tumor cells
acquire drug resistance. In dogs with TVT, overexpression
of permeability glycoprotein (P-gp) is one of the major

factors leading to multidrug resistance (MDR) (9,10).
MDR may occur with vincristine, vinblastine, doxorubicin,
prednisolone, and others (11). The dog in this case report
possibly had P-gp–mediated MDR, but this hypothesis
was not tested.
In contrast to antimicrotubule and anthracycline
agents, L-asparaginase is not affected by MDR.
L-asparaginase is an asparagine-specific enzyme whose
mechanism of action is based on depletion of plasma
asparagine. Some cancer cells are unable to synthesize
asparagine and are dependent on an exogenous source
of asparagine for survival, like lymphoma and mast cell
tumors (12). A protocol combining L-asparaginase and
vincristine was described as a successful treatment for
vincristine-resistant TVT cases (7). Since the dog in this
case had been previously treated with antimicrotubule and
anthracycline agents, the protocol established was based
on surgical cytology reduction obtained with surgery
in association with L-asparaginase and prednisone. No
data are available on the use of this protocol for treating
dogs with TVT, and so it is possible that the use of either
treatment alone could cause the response seen in this case.
The benefit of including prednisone in this protocol is
uncertain, because many vincristine-resistant TVT cases
may also be resistant to prednisone mediated by P-gp (13).
Surgical resection in combination with L-asparaginase
and prednisone may be an option for dogs with TVT that
does not respond to standard chemotherapy treatment
with vincristine and/or doxorubicin.
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